Yükleniyor... / Loading...
This study evaluates the chemotherapy drug Pemetrexed in patients with advanced or metastatic osteosarcoma (bone cancer). People who had received one prior chemotherapy regimen and had measurable disease and adequate organ function could take part. The study was carried out in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Histological diagnosis of high grade locally advanced or metastatic osteosarcoma * Must have one prior chemotherapy regimen for advanced disease * At least 1 unidimensional measurable lesion by computed tomography (CT) scan * Have a good performance status * Adequate organ function Exclusion Criteria: * Have a serious concomitant systemic disorder (for example active Human Immunodeficiency Virus infection) * Have brain metastases not adequately treated * Significant weight loss (that is more than 20%) over the previous 6 weeks before study entry * Inability or unwillingness to take folic acid or vitamin B12 supplementation and corticosteroids * Pregnant or breast-feeding